The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

The "Genomic Data Analysis and Interpretation Market Opportunities and Strategies to 2033" report has been added to ...

The genomics industry is set for growth due to advancements in personalized medicine, diagnostics, and biotech innovations.

Regeneron, San Diego-based biotech company Illumina and 17 health systems invested in the $320 million round. Regeneron ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

and auto-launch analysis either on instrument or in the cloud." At this point, the software team is ready to bring in other software components. They start with Real-Time Analysis, which is needed for ...

Another contributing factor is the transition to X sequencing ... portion of Illumina’s revenue. Moreover, the company’s strategic focus on multiomics, including the launch of new single ...

which is a competitor to Illumina technology, like its mid-range NextSeq 2000 sequencer, and the forthcoming launch of Aviti24 that combines sequencing and cell characteristic mapping in a single ...

Genomics is bringing in a new wave of money from an unlikely group of investors — health systems. More providers are ...

Stellaromics, a start-up that uses multiomics technology to help researchers understand the spatial organization of cells and tissues, has raised $80 million in a series B financing. Catalyst4, a ...

Sequins, a newly-funded start-up in the next generation sequencing (NGS) ecosystem, announced today the availability of their first commercial products ? the Sequins Metagenomics Core Control and ...